4D Molecular Therapeutics Q1 2023 Earnings Report

4D Molecular Therapeutics EPS Results

• Actual EPS: -$0.88
• Consensus EPS: -$0.88
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

4D Molecular Therapeutics Revenue Results

• Actual Revenue: $0.30 million
• Expected Revenue: $1.45 million
• Beat/Miss: Missed by -$1.15 million
• YoY Revenue Growth: N/A

4D Molecular Therapeutics Announcement Details

• Quarter: Q1 2023
• Date: 5/10/2023
• Time: N/A

4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.